INCY Incyte Corporation

136.16
+1.73  (1%)
Previous Close 134.43
Open 134.17
Price To book 28.47
Market Cap 27.88B
Shares 204,774,000
Volume 1,199,287
Short Ratio 2.12
Av. Daily Volume 2,874,010

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 various presentations (5) at ASCO June 3-5, 2017. Abstracts 9014, 4515, 4503, 3012, 6010.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017. Abstract 3003.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Pivotal program expected to begin in 2017.
Itacitinib (JAK1)
Treatment-naïve acute GVHD
Phase 3 trial to be initiated in 2017.
Baricitinib
Psoriatic arthritis
Phase 2 commenced February 2017.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal program to commence in 2017.
Ruxolitinib
Essential thrombocythemia
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 enrollment commenced March 2017.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. CRL received April 14, 2017.
Baricitinib
Rheumatoid arthritis
Phase 2 initiated October 2015
Ruxolitinib cream
Topical treatment of alopecia areata
Phase 3 initiated June 2016. Initial data due 2018
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 1/2 in combination with osimertinib (EGFR) expected to initiate 4Q 2016.
INCB39110 with osimertinib (EGFR)
Lung cancer
Ongoing
Epacadostat
Cancer - multiple tumor types
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 pivotal trial dosing initiation announced December 30, 2016.
Ruxolitinib - REACH 1
Graft versus host disease